Abstract Polatuzumab vedotin (Pola), a CD79b-targeting antibody-drug conjugate, was approved in China for use with bendamustine and rituximab (BR) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for hematopoietic stem cell transplantation (HSCT). Previous study, based on immature survival data and without considering post-progression treatment costs, found Pola-BR not cost-effective.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Shihui
Contact Shihui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack